Science TechnologyMonday, 27 July 2026·The Hindu - Science
India approves Qdenga as first dengue vaccine, with age 4-60 use and serotype coverage
In 2026, India’s drug regulator approved Qdenga, the country’s first dengue vaccine, for ages 4 to 60 years against four dengue serotypes.
Key highlights
Direct fact
In 2026, India’s drug regulator approved Qdenga, the country’s first dengue vaccine, for people aged 4 to 60 years against the four dengue serotypes DENV-1 to DENV-4.
Key specifics
- Qdenga is manufactured by the Japanese pharmaceutical company Takeda.
- The vaccine is said to protect against 4 dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4.
- It may be given to children and adults aged 4-60 years, regardless of prior dengue infection.
- More than 40 countries had already approved Qdenga before India’s approval.
- Takeda published clinical trial data in 2019, 2020 and 2024, which raised a specific safety concern.
Exam lens
Question type: Science and health technology, key facts: Qdenga, 2026 approval, Takeda, 4-60 years, DENV-1 to DENV-4, 40+ countries. TNPSC may ask India’s first dengue vaccine and its serotype coverage.